Table 2.
Time | Baseline | Year 1 | Year 2 | |||
---|---|---|---|---|---|---|
Group | OOCP | TSRF | OOCP | TSRF | OOCP | TSRF |
VAS patient satisfaction (0–100) | 88 ± 21 | 87 ± 19 | 84 ± 25 | 82 ± 23 | 82 ± 24 | 83 ± 23 |
No. of visits | 3.2 ± 1.9 | 3.8 ± 1.6* | 2.6 ± 1.6 | 3.5 ± 2.2** | ||
No. of phone calls | 1.8 ± 3.3 | 0.4 ± 0.8** | 0.7 ± 1.4 | 0.1 ± 0.3** | ||
DAS-28 | 3.0 ± 1.2 | 2.9 ± 1.0 | 2.6 ± 1.1 | 2.6 ± 1.0 | 2.7 ± 1.2 | 2.5 ± 1.0 |
CRP (mg/l) | 10.2 ± 7.2 | 10.1 ± 8.0 | 8.2 ± 9.9 | 5.7 ± 5.1* | 9.6 ± 8.8 | 5.5 ± 8.9* |
28-SJC (0–28) | 0.6 ± 1.5 | 0.6 ± 1.2 | 0.2 ± 0.5 | 0.3 ± 1.0 | 0.3 ± 0.9 | 0.4 ± 1.2 |
28-TJC (0–28) | 3.3 ± 5.7 | 2.4 ± 4.2 | 2.4 ± 4.7 | 2.1 ± 3.7 | 2.4 ± 4.9 | 2.3 ± 4.7 |
VAS pain (0–100) | 27 ± 25 | 26 ± 21 | 28 ± 26 | 28 ± 24 | 32 ± 27 | 29 ± 25 |
VAS patient global (0–100) | 33 ± 28 | 31 ± 25 | 33 ± 27 | 31 ± 26 | 32 ± 25 | 37 ± 29 |
VAS physician global (0–100) | 7.3 ± 14 | 5.5 ± 10 | 4.3 ± 8.1 | 5.1 ± 10 | 5.1 ± 10 | 6.3 ± 13 |
VAS fatigue (0–100) | 40 ± 27 | 37 ± 27 | 41 ± 28 | 37 ± 30 | 44 ± 29 | 39 ± 28 |
HAQ-DI score (0–3) | 0.6 ± 0.6 | 0.6 ± 0.6 | 0.7 ± 0.6 | 0.6 ± 0.6 | 0.8 ± 0.7 | 0.6 ± 0.7 |
EQ-5D | 0.8 ± 0.2 | 0.8 ± 0.1 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.1 |
VAS patient comfort (0–100) | 90 ± 16 | 91 ± 13 | 88 ± 18 | 87 ± 18 | 85 ± 21 | 86 ± 21 |
VAS physician satisfaction (0–100) | 95 ± 13 | 96 ± 11 | 95 ± 1.8 | 95 ± 13 | 96 ± 12 | 93 ± 16 |
VAS physician comfort (0–100) | 99 ± 6.5 | 99 ± 5.7 | 97 ± 8.1 | 96 ± 11 | 98 ± 9.1 | 95 ± 14 |
VAS patient inclusion (0–100) | 90 ± 17 | 90 ± 15 | 86 ± 21 | 86 ± 21 | 83 ± 22 | 85 ± 21 |
*p < 0.05; **p < 0.0005, OOCP vs. TSRF group (Student’s t test). DAS, Disease Activity Score; EQ-5D, European Quality of Life Index; HAQ-DI, Health Assessment Questionnaire Disability Index; No., number; OOCP, Open Outpatient Clinic Programme; pt, patient; SJC, swollen joint count; TJC, tender joint count; TSRF, traditional scheduled routine follow-up; VAS, visual analogue scale